Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background: U.S. Special Operations Forces Veterans are at increased risk for a variety of mental health problems and cognitive impairment associated with military service. Current treatments are lacking in effectiveness and adherence. Therefore, this study examined psychedelic treatment with ibogaine and 5-methoxy-N,N-dimethyltryptamine for trauma-related psychological and cognitive impairment among U.S. Special Operations Forces Veterans. Method: We conducted a survey of Veterans who completed a specific psychedelic clinical program in Mexico between 2017 and 2019. Questions probed retrospective reports of mental health and cognitive functioning during the 30 days before and 30 days after treatment. A total of 65 people completed treatment during this time frame and were eligible for contact. Of these, 51 (78%) completed the survey and were included in data analyses (mean age = 40; male = 96%; married = 55%; Caucasian/White = 92%; Operation Enduring Freedom/Operation Iraqi Freedom Service = 96%). Results: Results indicated significant and very large reductions in retrospective report of suicidal ideation (p < .001; d = −1.9), cognitive impairment (p < .001; d = −2.8), and symptoms of posttraumatic stress disorder (p < .001; d = −3.6), depression (p < .001; d = −3.7), and anxiety (p < .001; d = −3.1). Results also showed a significant and large increase in retrospective report of psychological flexibility (p < .001; d = 2.9) from before-to-after the psychedelic treatment. Increases in the retrospective report of psychological flexibility were strongly associated with retrospective report of reductions in cognitive impairment, and symptoms of posttraumatic stress disorder, depression, and anxiety (rs range −0.61 to −0.75; p < .001). Additionally, most participants rated the psychedelic experiences as one of the top five personally meaningful (84%), spiritually significant (88%), and psychologically insightful (86%) experiences of their lives. Limitations: Several limitations should be considered including the retrospective, self-report, survey design of the study, and the lack of randomization and blinding, thus making these finding preliminary. Conclusion: U.S. Special Operations Forces Veterans may have unique treatment needs because of the sequela of problems associated with repeated trauma exposure and the nature of the exposure. Psychedelic-assisted therapy with these under-researched psychedelics may hold unique promise for this population. However, controlled studies are needed to determine whether this treatment is efficacious in relieving mental health and cognitive impairment among U.S. Special Operations Forces Veterans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection
Kroenke, K., Spitzer, R. L., Williams, J. B. W., Monahan, P. O., & Löwe, B. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00004 · Cited by 4,741 · cited 1×
“The Generalized Anxiety Disorder 2item is used to assess presence of anxiety symptoms.(64,65) Respondents reported the frequency (01⁄4 “not at all” to 31⁄4 “nearly every day”) at which they experienced feeling anxious or worried onemonth before and onemonth after participating in the treatment program.”
MethodBond, F. W., Hayes, S. C., Baer, R. A., Carpenter, K. M., Guenole, N., Orcutt, H. K., Waltz, T., & Zettle, R. D. (2011) · Behavior Therapy · doi:10.1016/j.beth.2011.03.007 · Cited by 3,950 · cited 1×
“The Acceptance and Action Questionnaire II (AAQ-II) is a one-factor, seven-item measure used to assess psychological inflexibility or experiential avoidance.(69) In the present study, the degree of 4 Chronic Stress”
MethodPlummer, F., Manea, L., Trepel, D., & McMillan, D. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.11.005 · Cited by 1,882 · cited 1×
“The Generalized Anxiety Disorder 2item is used to assess presence of anxiety symptoms.(64,65) Respondents reported the frequency (01⁄4 “not at all” to 31⁄4 “nearly every day”) at which they experienced feeling anxious or worried onemonth before and onemonth after participating in the treatment program.”
MethodMeta-Analysis of the Efficacy of Treatments for Posttraumatic Stress Disorder
Watts, B. V., Schnurr, P. P., Mayo, L., Young-Xu, Y., Weeks, W. B., & Friedman, M. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08225 · Cited by 985
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Psychotherapy for Military-Related PTSD: A Review of Randomized Clinical Trials
Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015) · JAMA · doi:10.1001/jama.2015.8370 · Cited by 958
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Bisson, J. I., Ehlers, A., Matthews, R., Pilling, S., Richards, D., & Turner, S. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.021402 · Cited by 900
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
Cited by
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“In keeping with possible increases in openness (210) and connectedness (88, 271, 272), studies have shown that psychedelic use may be associated with increases in nature relatedness (273–275), pro-environmental behaviors (276) and more broadly experiences of personal meaning (81, 148, 209, 219, 277).”
BackgroundInfluentialPsilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca
Weiss, B., Wingert, A., Erritzoe, D., & Campbell, W. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-36184-3 · Cited by 33
“To reduce the burden on participants, the LEC-5 was adapted to contain nine types of adverse life events (ALE) including (1) natural disaster, fire, or explosion, (2) transportation or serious accident at home, work, or during a recreational activity, (3) physical assault, assault with a weapon, (4) sexual assault, (5…”
BackgroundDavis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068884 · Cited by 21
Self-citationMangini, P., Averill, L. A., & Davis, A. K. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00176 · Cited by 19
Self-citation
Metadata
- Authors
- Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T.
- Venue
- Chronic Stress
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 4
- Pages
- 2470547020939564-2470547020939564
- ISSN
- 2470-5470 (ISSN-L)
- OpenAlex
- W3041518543
- Cited by
- 84
- References
- 27
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. https://app.cochat.ai/papers/10.1177/2470547020939564
- The paper
- Davis, A. K., Averill, L. A., Sepeda, N. D., Barsuglia, J. P., & Amoroso, T. (2020). Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans. Chronic Stress. https://doi.org/10.1177/2470547020939564
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.